Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Metastatic Colorectal Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study leads
Nicholas P Tschernia, M.D.
Principal Investigator
National Cancer Institute (NCI)